Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Low grade lymphoma, Non-Hodgkin lymphoma (NHL)
Closed
Phase 3
This trial is looking at a new drug called GP2103 alongside chemotherapy to treat follicular lymphoma.
Doctors usually treat follicular lymphoma with chemotherapy and a monoclonal antibody. The chemotherapy they usually use is a combination of cyclophosphamide, vincristine and prednisolone (CVP). The monoclonal antibody they use is rituximab (Mabthera).
GP2013 is a monoclonal antibody that is similar, but not identical, to rituximab.
The researchers want to compare rituximab alongside CVP with GP2013 alongside CVP. The aim of the trial is to find out if GP2013 works as well rituximab to treat follicular lymphoma.
Recruitment start: 1 December 2011
Recruitment end: 18 December 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Edward Kanfer
Hexal AG
Novartis
Sandoz
Last reviewed: 31 Dec 2014
CRUK internal database number: 12289
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
